Last reviewed · How we verify
Janagliflozin plus metformin
Janagliflozin is an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption, combined with metformin which decreases hepatic glucose production and improves insulin sensitivity.
Janagliflozin is an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption, combined with metformin which decreases hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Janagliflozin plus metformin |
|---|---|
| Sponsor | Sihuan Pharmaceutical Holdings Group Ltd. |
| Drug class | SGLT2 inhibitor + biguanide combination |
| Target | SGLT2; metformin (mitochondrial complex I) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Janagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, promoting urinary glucose excretion independent of insulin. Metformin, a biguanide, decreases hepatic gluconeogenesis and enhances peripheral glucose uptake. Together, this combination provides complementary glucose-lowering effects through distinct mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Gastrointestinal disturbances (metformin-related)
- Polyuria
- Polydipsia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Janagliflozin plus metformin CI brief — competitive landscape report
- Janagliflozin plus metformin updates RSS · CI watch RSS
- Sihuan Pharmaceutical Holdings Group Ltd. portfolio CI